Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 1;19:190. doi: 10.1186/s12916-021-02068-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — Analysis of the immune microenvironment mechanism in TNBC patients. A–D The box diagram showing the distribution of activated NK cells (A) and the immune molecular and cellular characteristics, including regulatory macrophages (Mregs, B), BCR repertoire diversity (C) and tumour-infiltrating lymphocytes score (D). E, F Under different HRD status and distinct ACT responses, the patients with IFN-γ activity (E) and the expression of CTLA-4 (F) were diverse. P-value between the two (among multiple) groups was calculated by the Wilcoxon rank-sum (Kruskal-Wallis) test, the same below. ACT-S&HR-D: sensitive to ACT and HR deficiency (26 cases); ACT-S&HR-P: sensitive to ACT and HR proficiency (13 cases); ACT-R&HR-D: resistant to ACT and HR deficiency (22 cases); and ACT-R&HR-P: resistant to ACT and HR proficiency (22 cases). G–I The elevated expression of known cancer immunotherapy biomarkers, including CTLA-4 (G), PD-1 (H) and PD-L1 (I), were correlated with ACT-sensitive and HR proficiency (ACT-S&HR-P). The others mean all samples except ACT-S&HR-P